Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLS PharmaceuticalsASX:BLS +1.66%46 Cash-to-Debt is 1.42 as of Dec. 2025, which is 100% below its 10-year median of 10,000.00. GuruFocus rates ASX:BLS with a GF Score™ of 46/100 and a GF Value™ of A$0.71 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,355 Biotechnology companies, BLS Pharmaceuticals ranks worse than 73.21% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BLS Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2025 was 1.42.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, BLS Pharmaceuticalscould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for BLS Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
ASX:BLS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.42 Med: No Debt Max: No Debt
Current: 1.42
During the past 13 years, BLS Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 1.42. And the median was No Debt.
ASX:BLS's Cash-to-Debt is ranked worse than 73.21% of 1355
companies
in the Biotechnology industry
Industry Median: 7.29
vs ASX:BLS: 1.42
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
BLS Pharmaceuticals Cash-to-Debt Related Terms
BLS Pharmaceuticals Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:BLS vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, BLS Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals (ASX:BLS) has a Cash-to-Debt of 1.42 as of Dec. 2025. This is 100% below median its historical median of 10,000.00. Over the past decade, BLS Pharmaceuticals' Cash-to-Debt has ranged from 1.42 to 10,000.00. According to the industry distribution chart, BLS Pharmaceuticals ranks #992 out of 1355 companies in the Biotechnology industry, placing it in the top 73.2%.
Is BLS Pharmaceuticals' Cash-to-Debt too high?
BLS Pharmaceuticals' current Cash-to-Debt of 1.42 is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 1.42 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.29. BLS Pharmaceuticals' value of 1.42 is 80.5% below this industry median. Based on the distribution chart, BLS Pharmaceuticals ranks #992 out of 1355 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BLS Pharmaceuticals has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #992 out of 1355 companies for Cash-to-Debt. This places BLS Pharmaceuticals in the lower half of its industry. The industry median Cash-to-Debt is 7.29. BLS Pharmaceuticals' value of 1.42 is 80.5% below this benchmark. Historically, BLS Pharmaceuticals' own Cash-to-Debt has ranged from 1.42 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 7.29, BLS Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.29, based on 1,355 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLS Pharmaceuticals's current Cash-to-Debt of 1.42 is 80.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLS Pharmaceuticals's current Cash-to-Debt is 1.42, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (ASX:BLS) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.71, compared to a current price of A$0.92 — trading 29.6% above its estimated fair value. The current Cash-to-Debt is 1.42, which is 100% below median its 10-year median of 10,000.00 and 80.5% below the Biotechnology industry median of 7.29. BLS Pharmaceuticals' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For BLS Pharmaceuticals (ASX:BLS), the current Cash-to-Debt is 1.42 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of A$0.92 is trading 29.6% above its estimated GF Value™ of A$0.71.
GuruFocus considers BLS Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ASX:BLS:
Cash-to-Debt: 1.42 (100% below median its 10-year median of 10,000.00)
GF Value™: A$0.71 vs. price of A$0.92 (29.6% above fair value)
Industry Position: 80.5% below the Biotechnology median (#992 of 1355)
No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
46GF Score
Get the complete analysis for ASX:BLS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BLS has been successfully added to your 
